Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Medicin og biovidenskab

• Atrasentan 100%
• Chronic Renal Insufficiency 54%
• Type 2 Diabetes Mellitus 44%
• Placebos 40%
• Randomized Controlled Trials 40%
• Kidney 31%
• Endothelin Receptor Antagonists 15%
• Creatinine 14%
• Psychology Retention 13%
• Glomerular Filtration Rate 11%
• Chronic Kidney Failure 10%
• Albumins 10%
• Endothelin A Receptor Antagonists 8%
• Urine 8%
• Albuminuria 6%
• Safety 6%
• Body Surface Area 6%
• Renin-Angiotensin System 6%
• Kidney Transplantation 5%
• Intention 5%
• Renal Insufficiency 5%
• Dialysis 5%
• Anemia 4%
• Sodium 4%
• Therapeutics 4%
• Psychological Inhibition 4%
• Heart Failure 4%
• Research Personnel 4%
• Serum 2%
• Population 2%